

Product DataSheet

Anti-Human RSV-F (Palivizumab)

Catalog #: B593701

This product is for research use only and is not intended for diagnostic use.

Product Overview Lot Specific Information

Volume: Lot Specific*

Product Concentration: Lot Specific*

Total Quality: Lot Specific*

Indicates that this detail will be noted on the certificate of analysis that ships along with this product.

Product Information

Target : RSV

Clone: Palivizumab

Isotype: Human IgG1(K133A/S134A/T135A/S136A/K214R)-Kappa

Recommend Isotype Controls: Anti-HEL Human IgG1-Kappa Isotype control

Expression System: CHO

Purity: > 95% as determined by SDS-PAGE

Endotoxin: <1EU/mg, determined by LAL gel clotting assay

Immunogen: N/A

Sterility: 0.2 µM filtered

Formulation: PBS, pH 7.4, contains no stabilizers or preservatives

Alternative Names: Palivizumab; Synagis; MEDI-493; 188039-54-5; Anti-RSV fusion protein; Anti-RSV fusion glycoprotein; Anti respiratory syncytial virus fusion protein; Anti-RSV fusion

Recommended Dilution Buffer: ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives.

Storage: 2 weeks, 2-8°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.

Protocol Information: Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.